Drug Profile
Research programme: interleukin-11 derivatives - Bolder BioTechnology
Alternative Names: BBT 030; BBT 045Latest Information Update: 29 Oct 2021
Price :
$50
*
At a glance
- Originator Bolder BioTechnology
- Class Interleukins
- Mechanism of Action Interleukin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Reperfusion injury
Most Recent Events
- 29 Oct 2021 Discontinued - Preclinical for Reperfusion injury in USA (Parenteral) (Bolder Biotechnology pipeline, October 2021)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombocytopenia in USA
- 07 Nov 2006 Animal efficacy studies in progress